Cisplatin chemotherapy and renal function

Jie Zhang; Zhi-Wei Ye; Kenneth D Tew; Danyelle M Townsend

doi:10.1016/bs.acr.2021.03.008

Cisplatin chemotherapy and renal function

Adv Cancer Res. 2021:152:305-327. doi: 10.1016/bs.acr.2021.03.008. Epub 2021 Apr 28.

Authors

Jie Zhang¹, Zhi-Wei Ye², Kenneth D Tew², Danyelle M Townsend³

Affiliations

¹ Department of Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, SC, United States. Electronic address: zhajie@musc.edu.
² Department of Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, SC, United States.
³ Department of Pharmaceutical and Biomedical Sciences, Medical University of South Carolina, Charleston, SC, United States. Electronic address: townsed@musc.edu.

Abstract

Cisplatin has been a mainstay of cancer chemotherapy since the 1970s. Despite its broad anticancer potential, its clinical use has regularly been constrained by kidney toxicities. This review details those biochemical pathways and metabolic conversions that underlie the kidney toxicities. A wide range of redox events contribute to the eventual physiological consequences of drug activities.

Keywords: Alkylating agent; Antioxidants; Bioactivation; Cisplatin; Glutathione; Glutathione S-transferases; Kidney; Nephrotoxicity; Redox pathways; Transporters.

Publication types

Review

MeSH terms

Antineoplastic Agents* / pharmacology
Antioxidants / metabolism
Cisplatin / metabolism
Cisplatin / pharmacology
Glutathione / metabolism
Glutathione / pharmacology
Humans
Kidney / metabolism
Neoplasms* / drug therapy
Neoplasms* / metabolism
Oxidative Stress

Substances

Antineoplastic Agents
Antioxidants
Glutathione
Cisplatin

Abstract

Publication types

MeSH terms

Substances

Grants and funding